Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TIN-816 by Novartis for Sepsis: Likelihood of Approval
TIN-816 is under clinical development by Novartis and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs...
Data Insights
TIN-816 by Novartis for Acute Renal Failure (ARF) (Acute Kidney Injury): Likelihood of Approval
TIN-816 is under clinical development by Novartis and currently in Phase II for Acute Renal Failure (ARF) (Acute Kidney Injury)....